SCHEMBL30748846

SCHEMBL30748846

COc1cc(N2CCOCC2)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
HPGD P15428 5/20 0.47
THRB P10828 2/20 0.47
POLB P06746 1/20 0.47
HIF1A Q16665 2/20 0.43
MAPT P10636 9/20 0.43
KDM4E B2RXH2 3/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HTT P42858 1/20 0.42
INSR P06213 1/20 0.42
ALK Q9UM73 1/20 0.42
LGMN Q99538 1/20 0.41
PKM P14618 1/20 0.41
CHEK1 O14757 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL791178 1.00 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AHPGDTHRB
SCHEMBL790815 0.88 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AHIF1AMAPT
SCHEMBL17310043 0.87 SIRT6 (0.49) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL789720 0.82 LGMN (0.44) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL789351 0.82 MAPT (0.47) ALDH1A1MEN1KMT2AHPGDPOLB
SCHEMBL17394686 0.82 SMN1; SMN2 (0.41) MEN1KMT2AMAPTTSHRHTT
SCHEMBL17548072 0.81 LGMN (0.43) ALDH1A1MEN1KMT2APOLBMAPT
SCHEMBL30768488 0.81 DPP4 (0.36) ALDH1A1MEN1KMT2AHPGDTHRB
SCHEMBL28833460 0.79 LGMN (0.37) ALDH1A1MEN1KMT2AHPGDTHRB
SCHEMBL17637634 0.78 LGMN (0.43) ALDH1A1MEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALDH1A1 256/4885MEN1 301/4885KMT2A 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.